Bulk peptide supply, shipped from the north.

← Back to the journal Safety

Are peptides safe? What the research actually shows

7 min read

"Safe" is doing a lot of work in that question. Research peptides aren't reviewed by a drug regulator the way a pharmaceutical product is, so there's no single approval that settles the matter. What the risk actually comes down to is two separate things: what's really in the vial, and how that vial was handled before it got used. Both are checkable — most safety issues in this space trace back to one of the two.

What "purity" on a COA actually means

A purity figure on a certificate of analysis describes how much of the vial's content is the intended peptide, relative to everything else in it. A batch listed at 99% still carries roughly 1% of something else. That remainder can be leftover synthesis solvent, a peptide fragment that never finished assembling, or a degradation product formed after the batch was made. None of that shows up in a headline purity percentage on its own — a proper COA reports purity from HPLC analysis alongside a separate identity confirmation, usually mass spectrometry, that verifies the molecule is actually the compound the label claims.

Why the source matters more than the number on the label

Independent testing published on unregulated peptide products has repeatedly flagged the same handful of problems: bacterial endotoxins above safe limits for anything used in injection-based research, trace heavy metals, and certificates that don't actually correspond to the batch they're attached to. A generic COA reused across every listing on a site is a red flag; a real one is tied to a specific batch or lot number and comes from a lab with no commercial stake in the result.

Storage is a safety issue, not just a shelf-life one

Peptides are small proteins, and proteins degrade under heat, light, moisture and repeated freeze-thaw cycling. In their freeze-dried (lyophilized) form they're comparatively stable — typically fine for long periods at around -20°C, sealed and away from light. Once reconstituted into solution, that stability drops sharply: most peptides in liquid form should be kept refrigerated and used within days to a few weeks, and cycling a reconstituted vial in and out of the freezer is one of the most common ways a perfectly good batch turns into an inconsistent one.

What to actually check before relying on a batch

• A certificate tied to a specific batch or lot number, not a generic file reused across every product
• Purity from HPLC and identity confirmation from mass spectrometry — purity alone doesn't confirm what the molecule is
• Endotoxin and sterility results, for anything intended for injection-based research
• Storage conditions that match the peptide's current form — lyophilized and reconstituted are not stored the same way

None of this makes a compound "safe" in the way a licensed pharmaceutical is safe — that's a different bar entirely. But treating a research peptide with the same rigor as any other lab reagent — checking the batch record, not just the marketing — is what separates a usable sample from a guess.

← Back to the journal Guide

Peptides: the complete beginner's guide

8 min read

If you're opening your first vial, the terminology alone can be a lot. Here's the short version of what a research peptide actually is, why it shows up the way it does, and how to keep it usable.

What a peptide actually is

A peptide is a short chain of amino acids linked together — the same building blocks that make up proteins, just fewer of them and in a shorter sequence. That size is what makes peptides useful as research tools: they're small enough to synthesize precisely and study in isolation, but structured enough to interact with specific biological pathways, which is why so much of the current research interest sits here rather than with larger, more complex proteins.

Why research peptides arrive as a freeze-dried powder

Almost every peptide in this catalog ships lyophilized — freeze-dried into a stable powder rather than supplied in solution. The process freezes the peptide, then removes the water by sublimation under vacuum, leaving the molecular structure intact. Water is the main driver of degradation in a peptide, so removing it is what lets a batch stay stable for a long time rather than a few days. It's also why lyophilized peptides tolerate transit far better than reconstituted ones — though we still ship every box cold-chain as an added safeguard.

Reading the spec sheet

Each listing in our catalog states the total peptide content per vial and the box size it ships in — for example, "10mg × 10 vials" means each of the ten vials in that box contains 10mg of peptide. The batch or lot number is what ties a given box back to its certificate of analysis, so it's worth keeping a record of which batch you received.

Storage basics

• Lyophilized (unopened powder): around -20°C, sealed, away from light and moisture. Stable for extended periods when kept this way.
• Reconstituted (in solution): refrigerated at roughly 2–8°C, and used within a defined window — typically days to a few weeks depending on the specific peptide and diluent.
• Avoid freeze-thaw cycling: once a vial is reconstituted, repeatedly freezing and thawing it degrades the peptide faster than steady refrigeration does.

A short glossary

HPLC

High-Performance Liquid Chromatography — the standard method for measuring how much of a sample is the intended peptide versus everything else in the vial.

COA

Certificate of Analysis — the lab document reporting a batch's purity and identity test results.

Lyophilized

Freeze-dried into a stable powder by freezing the compound, then removing water under vacuum.

Sequence

The specific order of amino acids that makes up the peptide — what actually defines which compound it is.

Endotoxin

A bacterial byproduct that can remain in a poorly manufactured batch; tested for separately from purity.

Batch / Lot number

The identifier tying a specific production run to its certificate of analysis.

← Back to the journal Comparison

BPC-157 vs. TB-500: which for tissue-repair research?

6 min read

BPC-157 and TB-500 are the two most-studied peptides in tissue-repair research, and they're frequently mentioned in the same breath. They aren't the same kind of molecule, though, and they don't work through the same mechanism — which is exactly why researchers often study them together rather than treating one as a substitute for the other.

Two different molecules

BPC-157 is a synthetic 15-amino-acid sequence, derived from a partial sequence of a protective protein found in human gastric juice. TB-500 is a synthetic peptide corresponding to Thymosin Beta-4, a naturally occurring 43-amino-acid protein found throughout the body and best known as the major actin-regulating protein inside cells.

How each one is believed to work

BPC-157's research profile centers on angiogenesis — prompting the formation of new blood vessels — largely through upregulating VEGFR2 signaling and nitric-oxide pathways. Because that effect is local to where it's applied, most of the preclinical interest sits with tissues that depend heavily on a fresh blood supply to repair: tendons, ligaments and the gut lining.

TB-500's research profile centers on actin regulation — the scaffolding proteins that let cells move. Rather than building new vasculature, it's studied for how it mobilizes and migrates repair cells to an injury site, which is a more systemic mechanism. That's shown up most in research on muscle, skin and cardiac tissue.

Why they're often paired instead of compared

Put simply: BPC-157 research is largely about building the vascular supply a repair site needs, while TB-500 research is largely about moving the cells that use it there. The two mechanisms are complementary rather than redundant, which is the usual justification in the literature for studying them as a blend — it's why combination products like GLOW and KLOW pair them with GHK-Cu rather than treating either peptide on its own as sufficient.

What the evidence actually is

It's worth being direct about the state of the research: both compounds are studied almost entirely in preclinical, animal-model settings. Neither has completed controlled human efficacy trials. That doesn't make the mechanistic research uninteresting, but it does mean anything framed as an established human outcome is getting ahead of what's actually been published.